IRVINE, California, March 31, 2016 /PRNewswire/ --
Syneron Medical Ltd. (NASDAQ: ELOS) a global leader in aesthetic medical devices, today announced the presentation of 11 scientific abstracts at the Annual Conference of the American Society of Laser Medicine and Surgery (ASLMS). During the conference, industry luminaries will present new and breakthrough findings demonstrating safety and efficacy from clinical studies using Syneron Candela technologies for treating skin pigmentations, removing tattoos, removing hair and restoring vaginal health. The 36th annual conference will take place March 30 through April 3, 2016 at the Sheraton Boston Hotel/Hynes Convention Center in Boston, Mass.
Seven abstracts will demonstrate the performance of the brand's customizable, picosecond PicoWay® lasers for the removal of tattoos from an array of skin types, the correction of skin pigmentation and histological findings showing the effects of photoacoustic treatments on skin. Additional abstracts focus on the efficacy of permanent laser hair removal featuring the combination of an alexandrite 755nm laser with the award-winning elos® technology as well as impressive results from a study on Profound®, the first microneedle based fractional radiofrequency device to have a 100 percent response rate for rebuilding collagen, elastin and hyaluronic acid. Two abstracts will feature the company's established CO2RE platform, offering a range of solutions for resurfacing, wrinkle and scar reduction, pigmentation correction, and now the newly released CO2RE® Intima treatment, for restoring vaginal health.
"We have been developing, innovating and advancing energy based devices for more than four decades," said Dr. Shimon Eckhouse, Chairman of the Board, Syneron Candela. "With our experience, strong IP position and know-how, we have the ability to continuously innovate across our portfolio, anticipating trends and presenting our customers with the most advanced, highly-effective systems available. The strong clinical results presented at ASLMS prove that Syneron Candela continues to deliver scientific innovation, clinical excellence and great business opportunities for our customers."
Syneron Candela's ultrasound based UltraShape body shaping system will also be discussed at a variety of conference forums including the Non-Invasive Body Contouring Workshop and the Non-Invasive Body Contouring segment during the Annual ASLMS Tech Connect programs. All of the Syneron Candela products can be seen at the Syneron Candela booth #201.
Presentations on the company's leading picosecond technology are as follows:
Title: Novel Method for Treatment of Melasma with a 532nm Picosecond Laser Author: David Friedman, Dr. David Friedman Skin & Laser Center, Jerusalem, Israel Date and Time: Friday, April 1 at 1:00 p.m. Sessions: Cutaneous Applications - Picosecond Location: Hynes Auditorium Abstract: LB4
Title: Comparison Study of a 532/1064nm Picosecond Laser vs. a 532/1064nm Nanosecond Laser in the Treatment of Multi-Colored Tattoos in Asians and Comparison Study of a 532/1064nm Picosecond Laser vs. a 532/1064nm Nanosecond Laser in the Treatment of Black Tattoos in Asians Authors: Taro Kono, Samantha Shek, Henry Chan, William Groff, Kotaro Imagawa, Muneo Miyasaka; Tokai University, Isehara, Japan; University of Hong Kong, Hong Kong, China; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA; Cosmetic Laser Dermatology, San Diego, CA Date and Time: Friday, April 1 at 1:07 p.m. Sessions: Cutaneous Applications - Picosecond Location: Hynes Auditorium Abstract: 38A/B
Title: A Single Center Cohort Study for the Removal of Tattoos and Pigmented Lesions Using a 1064/532nm Dual Wavelength Picosecond Laser Authors: Thomas Proebstle; University Medical Center Mainz, Mainz, Germany Date and Time: Friday, April 1 at 1:21 p.m. Sessions: Cutaneous Applications - Picosecond Location: Hynes Auditorium Abstract: 39
Title: Comparison Study of a 532nm Picosecond Laser vs. a 532nm Nanosecond Laser in the Treatment of Pigmented Lesions in Asians Authors: Taro Kono, Samantha Shek, Henry Chan, William Groff, Kotaro Imagawa, Muneo Miyasaka; Tokai University, Isehara, Japan; University of Hong Kong, Hong Kong, China; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA; Cosmetic Laser Dermatology, San Diego, CA Date and Time: Friday, April 1 at 1:28 p.m. Sessions: Cutaneous Applications - Picosecond Location: Hynes Auditorium Abstract: 40
Title: Dual Wavelength Picosecond Laser Tattoo Removal: A Blinded Multi-Center Study Authors: Tina Alster, Arielle Kauvar, Eric Bernstein; Washington Institute of Dermatologic Laser Surgery, Washington, DC; New York Laser and Skin Care, New York, NY; Main Line Center for Laser Surgery, Ardmore, PA Date and Time: Friday, April 1 at 1:49 p.m. Sessions: Cutaneous Applications - Picosecond Location: Hynes Auditorium Abstract: 36
Title: Histologic Evaluation of In Vivo Human Skin Following Fractioned Treatment with High Intensity 1064 and 532nm Picosecond Pulses Authors: Arielle Kauvar, Kevin Schomaker, Tuvia Dror-Kutcher, Jayant Bahwalker, Ruthie Amir; New York Laser & Skin Care, NY; Syneron Candela, Yokneam, Israel Date and Time: Friday, April 1 at 3:42 p.m. Sessions: Cutaneous Applications - Picosecond Location: Hynes Auditorium Abstract: LB7
The Profound presentation will be featured as follows:
Title: Clinical Trial Assessing Treatment with Microneedle-based Fractional Radiofrequency for Cellulite Authors: Leyda Bowes, Miami, FL Date and Time: Saturday, April 2 at 3:51 p.m. Sessions: Cutaneous Applications - New Devices and Novel Data for Body Contouring Location: Hynes Auditorium Abstract: 59
Abstracts featuring the company's established CO2RE platform will be presented in the two sessions below:
In the first session, César Arroyo, M.D. will discuss clinical trial results from a CO2RE Intima study resulting in proven remodeling of vaginal and vulvar tissue and a 94% patient satisfaction rate.
"I led the initial clinical study on CO2RE Intima at H. M. Monteprincipe Hospital in Madrid. Of the 21 women treated, 94 percent were satisfied with the treatment, which is a very high satisfaction rate for an aesthetic procedure," said César Arroyo, M.D. "I have had previous experience using other technologies for this type of vaginal treatment, both Er:YAG and radiofrequency. I found the CO2 technology of CO2RE Intima to be a more effective treatment because it both ablates and coagulates providing the type of fractional impact that is most effective on mucosal tissue. In addition, it can be used to treat all three areas: vaginal canal, introitus and vulva."
Title: Sexual Function and Overall Satisfaction after Fractional CO2 Laser Vaginal Rejuvenation Treatment in Premenopausal Women: A Pilot Study & Short Term Results Authors: César Arroyo, Ruthie Amir, Konika Schallen; Hospital Monteprincipe, Madrid, Spain; Syneron Medical, Yokneam, Israel; Syneron Medical, Jacksonville, FL Date and Time: Saturday, April 2 at 4:30 p.m. Sessions: Women's Health - Pelvic Floor Dysfunction Location: Hynes 107 Abstract: 185
Title: Histological Evaluation for Laser Depth of Ex Vivo Abdominoplasty Skin Following Fractionated Treatment with a High Intensity Traditional, Fractional and Fusion Carbon Dioxide Laser Authors: Jill Waibel, Adam Wulkan, Ashley Rudnik; Miami Dermatology and Laser Institute; University of Miami, Miami, FL Date and Time: Sunday, April 3 at 7:23 a.m. Sessions: Cutaneous Applications - Advances in Fractionated Devices & Late Breaking Location: Hynes Auditorium Abstract: LB17
Finally a presentation on the combination of alexandrite laser and elos® technologies, a first, will be evaluated for its efficacy on permanent hair reduction.
Title: Long Term Follow up Using a Recently Developed Radiofrequency Energy - Alexandrite Laser Hair Removal Device Authors: Jerome Garden, Megan Calderon, Pedram Gerami; Northwestern University; Physicians Laser and Dermatology Institute, Chicago, IL Date and Time: Sunday, April 3 at 8:43 a.m. Sessions: Cutaneous Applications - Advances in Fractionated Devices & Late Breaking Location: Hynes Auditorium Abstract: LB21
The American Society for Laser Medicine and Surgery, Inc. (ASLMS) is the world's largest scientific organization dedicated to promoting research, education and high standards of clinical care in the field of medical laser applications. It provides a forum for the exchange of scientific information and participates in communicating the latest developments in laser medicine and surgery to clinicians, research investigators, government and regulatory agencies, and the public.
About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
SOURCE Syneron Medical Ltd.